Clinical Trial

Evaluating Intermittent Fasting In Individuals At High Risk ForPancreatic Cancer Undergoing Screening

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
To learn whether an eating pattern called intermittent fasting (IF) is tolerable and feasible for individuals at high risk of pancreatic cancer and whether IF is associated with changes in biological markers, including metabolic, inflammatory, microbiome, and imaging-related markers.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-01.
Trial Details
NCT Number NCT07513116
Lead Sponsor M.D. Anderson Cancer Center
Conditions Evaluating, Intermittent Fasting, Pancreatic Cancer
Enrollment 20 participants
Start Date 2026-09-17
Primary Completion 2027-03-30 (estimated)
Study Completion 2029-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-14